newsfilter
← Latest News
PR Newswire·

The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners

  • The Institute for Follicular Lymphoma Innovation (IFLI) appointed Mehrdad Mobasher, M.D., M.P.H. & Carol O'Hear, M.D., Ph.D. as Executive Partners on Oct. 21, 2025.
  • David McCullagh, Managing Director of IFLI, stated the appointees will provide strategic leadership & drug development expertise to elevate partnerships & guide portfolio companies.
  • Dr. Mobasher brings over two decades of hematology/oncology experience, most recently serving as Chief Medical Officer, Hematology at BeOne (formerly BeiGene).
  • Dr. Mobasher previously held leadership roles at Zai Lab, Corvus Pharmaceuticals, & Genentech, where he led global development for venetoclax.
  • Dr. O'Hear currently serves as SVP of Clinical Development & Chief Medical Officer at Exelixis with over two decades in drug discovery & clinical development.
  • Dr. O'Hear previously served at Gilead leading the magrolimab program & at Genentech as Global Development Leader for mosunetuzumab & glofitamab.
  • IFLI is a non-profit foundation dedicated to accelerating innovative treatment options for follicular lymphoma through grants, partnerships, & venture philanthropy.
  • The foundation aims to advance research, commercialization of novel therapeutics, & understanding of follicular lymphoma biology.